• Username (E-mail)
  • Password
Dow 19,827 0.5%  EStoxx50 3,284 -0.5%  Nikkei 18,891 -1.3%  EUR 1.0739 0.3% 
Nasdaq 5,555 0.3%  FTSE100 7,153 -0.6%  Yen 113.5080 -0.7%  Oil 55.0 -1.0% 
S&P500 2,271 0.3%  DAX 11,583 -0.4%  GBP 1.2462 0.7%  Gold 1,214 1.7% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

02/06/2012 02:55:58 AM
02/06/2012 02:55:58 AM UTC-0500

Vertex Pharmaceuticals Inc. Neutral

The analysts of Goldman Sachs Group Inc. have rated Vertex Pharmaceuticals with a Neutral rating. The price target was set to 40.00 $. At a current price of the Vertex Pharmaceuticals stock of 81.34 $ this means a downside potential of -50.82%.
Summary: Vertex Pharmaceuticals Inc. Neutral
Company:
Vertex Pharmaceuticals Inc.
Analyst:
Goldman Sachs Group Inc.
Price Target:
40.00 $
Current Rating:
Neutral
Price*:
38.25 $
Distance to Target Price*:
4.58%
Previous Rating:
Downgrade
Latest Price:
81.34 $
Distance Price Target:
-50.82%
Analyst Name::
-
P/E Ratio*:
-

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/14/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
12/05/12
Vertex Pharmaceuticals RBC Capital Markets
11/13/12
Vertex Pharmaceuticals Credit Suisse Group
11/05/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
11/02/12
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Latest Analyst Opinions
01/20/17 Nemetschek Commerzbank AG
01/20/17 HeidelbergCement DZ BANK
01/20/17 Apple Macquarie Research
01/20/17 Microsoft Goldman Sachs Group Inc.
01/20/17 Diageo Goldman Sachs Group Inc.
01/20/17 Reckitt Benckiser Group Goldman Sachs Group Inc.
01/20/17 Tate & Lyle Goldman Sachs Group Inc.
01/20/17 Software Oddo Seydler Bank AG
01/20/17 Unilever Goldman Sachs Group Inc.
01/20/17 Unilever Goldman Sachs Group Inc.
01/20/17 Ahold Delhaize Goldman Sachs Group Inc.
01/20/17 LVMH Moet Hennessy Louis Vuitton Goldman Sachs Group Inc.
01/20/17 Uniper Barclays Capital
01/20/17 TAG Immobilien Morgan Stanley
01/20/17 Banco Santander Central Hispano UBS AG
01/20/17 Vivendi Goldman Sachs Group Inc.
01/20/17 Wirecard Commerzbank AG
01/20/17 Scout24 Commerzbank AG
01/20/17 RHÖN-KLINIKUM Commerzbank AG
01/20/17 OSRAM Licht Commerzbank AG
01/20/17 Continental Morgan Stanley
01/20/17 Volvo (B) Morgan Stanley
01/20/17 Renault Morgan Stanley
01/20/17 Peugeot Morgan Stanley
01/20/17 Volkswagen vz Morgan Stanley
01/20/17 Daimler Morgan Stanley
01/20/17 BMW Morgan Stanley
01/20/17 KION GROUP Morgan Stanley
01/20/17 Linde Warburg Research
01/20/17 Pfeiffer Vacuum Technology Warburg Research
01/20/17 Intesa Sanpaolo Kepler Cheuvreux
01/20/17 SAFRAN Kepler Cheuvreux
01/20/17 Walmart Stifel, Nicolaus & Co., Inc.
01/20/17 RHÖN-KLINIKUM Baader Bank
01/20/17 CANCOM Baader Bank
01/20/17 Capital Stage Oddo Seydler Bank AG
01/20/17 WACKER CHEMIE Hauck & Aufhäuser Privatbankiers KGaA
01/20/17 CompuGroup Medical HSBC
01/20/17 Infineon Technologies Commerzbank AG
01/20/17 Hornbach Commerzbank AG
01/20/17 SAFRAN UBS AG
01/20/17 Banco Bilbao Vizcaya Argentaria UBS AG
01/20/17 Compagnie de Saint-Gobain Deutsche Bank AG
01/20/17 Aurubis Deutsche Bank AG
01/20/17 ASML Deutsche Bank AG
01/20/17 Ahold Delhaize Deutsche Bank AG
01/20/17 Commerzbank Deutsche Bank AG
01/20/17 Deutsche Post Jefferies & Company Inc.
01/20/17 Banco Santander Central Hispano Jefferies & Company Inc.
01/20/17 Sanofi Jefferies & Company Inc.